IRAK-4 Antibody (5-RY38): sc-134368
- IRAK-4 Antibody (5-RY38) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant IRAK-4 protein of human origin
- recommended for detection of IRAK-4 of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IRAK-4 Antibody (5-RY38). This work is in progress.
IRAK-4 Antibody (5-RY38) is a mouse monoclonal IgG1 antibody that detects IRAK-4 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). IRAK-4 is a crucial mediator in the signaling pathways of Toll-like receptors and interleukin-1 receptors, playing a vital role in the innate immune response. IRAK-4 is primarily located in the cytoplasm, where IRAK-4 acts as a key component in the activation of downstream signaling cascades, including the NFkB and MAP kinase pathways. Proper functioning of IRAK-4 is essential for the immune system′s ability to respond to pathogens; IRAK-4 deficiency can lead to severe immunological consequences, such as recurrent bacterial infections and a diminished response to lipopolysaccharides and interleukin-1. Given IRAK-4′s pivotal role in immune signaling, IRAK-4 is not only important for understanding immune responses but also represents a promising target for therapeutic interventions aimed at enhancing immune function or treating immune-related disorders. Anti-IRAK-4 antibody (5-RY38) is therefore an invaluable tool for researchers investigating the mechanisms of innate immunity and the potential for drug development targeting this critical protein.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IRAK-4 Antibody (5-RY38) References:
- Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. | Picard, C., et al. 2011. Clin Microbiol Rev. 24: 490-7. PMID: 21734245
- U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. | Smith, MA., et al. 2019. Nat Cell Biol. 21: 640-650. PMID: 31011167
- Targeting IRAK4 for Degradation with PROTACs. | Nunes, J., et al. 2019. ACS Med Chem Lett. 10: 1081-1085. PMID: 31312412
- Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. | Wiese, MD., et al. 2020. Expert Opin Investig Drugs. 29: 475-482. PMID: 32255710
- IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. | Somani, VK., et al. 2022. Gastroenterology. 162: 2047-2062. PMID: 35271824
- The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. | Pereira, M., et al. 2022. Cell Rep. 40: 111225. PMID: 35977521
- IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. | Lavazais, S., et al. 2023. Sci Transl Med. 15: eabj3289. PMID: 36791209
- Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. | García-García, A., et al. 2023. J Exp Med. 220: PMID: 36880831
- A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway. | Yoon, SB., et al. 2023. Acta Pharm Sin B. 13: 1093-1109. PMID: 36970199
- Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis. | Kang, C., et al. 2023. Front Immunol. 14: 1276512. PMID: 37915574
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IRAK-4 Antibody (5-RY38) | sc-134368 | 100 µg/ml | $339.00 |